Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03118986

RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy

Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis. Olanzapine improves CINV control in adult cancer patients, has a track record of safe use in children with psychiatric illness, does not interact with chemotherapy and is inexpensive. We hypothesize that the addition of olanzapine to standard antiemetics will improve chemotherapy-induced vomiting (CIV) control in children receiving highly emetogenic chemotherapy

Recruiting

Interested in participating?

Request Info

Key information

Age range

30 month–18 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Cancer Care Manitoba, Winnipeg, Manitoba, Canada

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Planned receipt of HEC or cyclophosphamide ≥ 1 g/m2/day (≥ 33 mg/kg/day) for cancer treatment or autologous or allogeneic HSCT conditioning.81,82 Examples of HEC are: busulfan IV (myeloablative dosing), carboplatin ≥175mg/m²/dose, cisplatin ≥12mg/m²/dose, cytarabine ≥3g/m²/day, melphalan >140mg/m², methotrexate ≥12g/m²/dose and thiotepa ≥300mg/m²/dose.

Plan for inpatient admission from administration of first study drug dose until 24 hours following administration of last study drug dose.

Body weight of at least 12.5 kg

2.5 to < 18 years of age. Note that the minimum age requirement corresponds to an approximate body weight of 12.5 kg.

Samples for all laboratory tests will be obtained within one week prior to administration of the first chemotherapy dose of the study chemotherapy block or the first HSCT conditioning dose:

  • Plasma creatinine within 1.5 times the upper limit of normal for age.
  • Amylase within age-appropriate limits
  • Plasma conjugated bilirubin within ≤ 3x upper limit of normal for age unless attributable to Gilbert's Syndrome
  • ALT ≤ 5x upper limit of normal for age

Baseline ECG within the month prior to study drug administration without known clinically significant abnormalities including pathologic prolongation of QTc

A plan for scheduled, round-the-clock receipt of ondansetron, granisetron or palonosetron for antiemetic prophylaxis during administration of chemotherapy or HSCT conditioning.

Negative pregnancy test if female of childbearing potential

Patients of childbearing potential must consent to use adequate contraception (males and females) or agree to practice abstinence

Parent or child able to speak a language in which the (modified Pediatric Adverse Event Rating Scale (PAERS) is available.

Optional: Child participants in the optional assessment of nausea severity must be 4 to 18 years of age. Child and a parent/guardian must be English, Spanish or French-speaking. The Pediatric Nausea Assessment Tool58 (PeNAT) is validated in English-speaking children 4 to 18 years old with an English-speaking parent/guardian and has been translated into Spanish and French. The MAT is available in English, Spanish and French.

Treatment and study plan

Olanzapine

Drug

olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight

Placebo oral tablet

Drug

Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine

Primary outcomes

  1. Rate of CIV control during the acute phase

    Time frame: up to 8 days

    Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase

  2. Rate of CIV control during the acute phase

    Time frame: up to 8 days

    Partial control is defined as no more than two vomits or retches during any 24-hr period

Secondary outcomes

  1. complete and partial CINV control

    Time frame: up to 1 month

    Complete CIV control is no vomiting/retching and no use of breakthrough antiemetic agents during phase, Partial control is defined as no more than two vomits or retches during any 24-hr period

  2. Safety profile of olanzapine based on toxicities

    Time frame: up to 1 month

    Based on descriptive statistics on reported toxicities.

  3. Safety profile of olanzapine based on weight

    Time frame: up to 1 month

    Based on descriptive statistics on reported body weight

  4. Safety profile of olanzapine based on Pediatric Adverse Event Rating Scale (PAERs)

    Time frame: up to 1 month

    Based on descriptive statistics on reported PAERs, will describe the most reported and most bothersome adverse events reported in the PAERs questionnaire.

  5. Safety profile of olanzapine based on prolactin

    Time frame: up to 1 month

    Based on descriptive statistics on reported prolactin, will report incidence of abnormal prolactin values comparing the two arms

  6. Safety profile of olanzapine based on amylase

    Time frame: up to 1 month

    Based on descriptive statistics on reported amylase, will report incidence of abnormal amylase values comparing the two arms

  7. Safety profile of olanzapine based on creatine phophotase

    Time frame: up to 1 month

    Based on descriptive statistics on reported creatine phophotase, will report incidence of abnormal creatine phophotase values comparing the two arms

  8. Safety profile of olanzapine based on triglycerides

    Time frame: up to 1 month

    Based on descriptive statistics on reported triglycerides, will report incidence of abnormal triglyceride values comparing the two arms

  9. Impact of olanzapine on HSCT outcomes on incidence of veno-occlusive disease

    Time frame: From first HSCT conditioning dose until 100 days post-HSCT

    Looking at incidence of veno-occlusive disease

  10. Impact of olanzapine on HSCT outcomes on incidence of GVHD

    Time frame: From first HSCT conditioning dose until 100 days post-HSCT

    Looking at incidence of GVHD between the two arms

  11. Impact of olanzapine on HSCT outcomes on severity of GVHD

    Time frame: From first HSCT conditioning dose until 100 days post-HSCT

    Comparing the incidence of the different maximal grades of GVHD between the two arms

  12. Association between PeNAT and MASCC Antiemesis Tool (MAT) scores

    Time frame: up to 1 month

    taking maximum daily PeNAT scale score and maximum nausea experience in MAT will estimate the degree of association between PeNAT and MAT

Study contacts

Contact information is provided by the study sponsor or research team.

Lee Dupuis, RPh, PhD

CONTACT

[email protected]

416-813-7762

Muhammad Ali, MD

CONTACT

[email protected]

416-813-7654 ext. 201438

Sponsors and collaborators

Lead sponsor

The Hospital for Sick Children

Other

Collaborators

  • CancerCare Manitoba
  • Children's Mercy Hospital Kansas City
  • Columbia University
  • Medical University of South Carolina
  • Nationwide Children's Hospital
  • St. Justine's Hospital
  • University of California, San Francisco
  • University of North Carolina, Chapel Hill

Registry information

Official study title

Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-induced Vomiting in Children Receiving Highly Emetogenic Chemotherapy

Important dates

Study start
2017
Primary completion
2026
Study completion
2026
First posted
Apr 18, 2017
Registry last updated
Oct 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.